LEP and breast carcinoma: Furthermore, taking into account potential off‐target effects of fatostatin as previously reported [58], the role of SREBP‐1 was further confirmed by gene silencing of SREBP‐1 (Fig. 5), allowing to conclude that SREBP‐1‐mediated lipogenesis is required for FAO stimulation by leptin in breast cancer cells.